Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use DELSTRIGO safely and effectively. See full prescribing information for DELSTRIGO. DELSTRIGO® (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
DELSTRIGO® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14)].
- generic_name
- doravirine, lamivudine, and tenofovir disoproxil fumarate
- product_names
- doravirine, lamivudine, and tenofovir disoproxil fumarate
- ndc
- 0006-5007, 0006-5007-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en